Kaczmarek I, Schmauss D, Sodian R, Beiras-Fernandez A, Oberhoffer M, Daebritz S, Schoenberg S O, Reichart B
Department of Cardiac Surgery, Ludwig Maximilians University, Munich, Germany.
J Heart Lung Transplant. 2007 Jan;26(1):89-92. doi: 10.1016/j.healun.2006.10.008.
Tacrolimus is a macrolide immunosuppressant frequently used after solid-organ transplantation. Moderate and severe neurologic side effects have been reported in patients receiving tacrolimus. Cerebral neurotoxicity is a rare but fatal calcineurin inhibitor-related complication, especially in kidney and liver transplant recipients. Often a reduction or a change in immunosuppressive regimen is the only means of clinical management. Herein we report a case of a 31-year-old man who developed cerebellar atrophia while under immunosuppressive therapy 9 years after heart transplantation. His neurologic constitution ameliorated after an immunosuppressant switch from tacrolimus to sirolimus.
他克莫司是一种大环内酯类免疫抑制剂,常用于实体器官移植后。接受他克莫司治疗的患者曾有中度和重度神经副作用的报道。脑神经毒性是一种罕见但致命的与钙调神经磷酸酶抑制剂相关的并发症,尤其在肾移植和肝移植受者中。通常减少或改变免疫抑制方案是临床管理的唯一手段。在此,我们报告一例31岁男性患者,该患者在心脏移植9年后接受免疫抑制治疗期间出现小脑萎缩。在将免疫抑制剂从他克莫司换为西罗莫司后,他的神经状况有所改善。